mRNA-based vaccines have a good safety profile and can be rapidly, flexibly, and cost-effectively manufactured. In addition, mRNA sequences can be designed to encode various antigens, which is highly significant for individualized therapies. mRNA vaccine is well suited to target tumor-specific antigens and has been studied in several preclinical and clinical trials. CD BioSciences fully supports mRNA vaccine development services for PC. With extensive experience in custom mRNA synthesis, mRNA optimization, and mRNA delivery system development, our team of experts is confident to provide the best service in mRNA vaccine development for PC.
mRNA—a powerful and versatile cancer vaccine platform
mRNA vaccines consist of one or more nucleic acids that encode single or multiple vaccine antigen candidates, directly transported into the host cell via a combination of customized delivery vectors. Compared with other cancer vaccines, such as peptide-based vaccines, tumor cell-based vaccines, and dendritic cell-based vaccines, mRNA-based vaccines stand out for the following reasons:
- mRNA vaccine can provide enhanced anti-tumor immunity based on humoral and cellular adaptive immune response by encoding multiple antigens simultaneously.
- As a type of nucleic acid vaccine, mRNA vaccines are safer than DNA vaccines because they are non-integrating, highly degradable, and have no potential for insertion of mutations.
- Compared to protein or cell-mediated vaccines, the in vitro-transcribed (IVT) mRNA is free of cellular or pathogenic viral components, is free of infection potential, and has been shown to be well tolerated.
- With a mature mRNA manufacturing process and formulation platform, mRNA cancer vaccines can be rapidly mass produced.
Fig. 1 Typical mechanism of mRNA vaccine. (Dai, Hong, et al., 2022)
Custom mRNA vaccine development services for PC
- Identification of potential antigens of PC
The primary mechanism of mRNA vaccines is based on the identification of specific tumor antigens, followed by activation of the immune system to recognize and eliminate cancer cells. Our target identification and evaluation in the platform have been proven to be reliable, accurate, and effective in several tumor models. Combining the next-generation sequencing platform, bioinformatics, and optimal computational approach, we can assist our customers in identifying potential antigens in PC, laying the foundation for the development of PC mRNA vaccines.
- mRNA vaccine manufacturing
Based on our many years of experience in the mRNA vaccine field and our state-of-the-art manufacturing facilities, we can facilitate the production and efficiency of mRNA vaccines during early development. We are capable of offering innovative and integrated services, including different types of mRNA vaccine production, adjuvant development, and mRNA delivery system development. Our mRNA vaccine manufacturing platform is novel, highly flexible, scalable, and cost-effective.
- mRNA vaccine quality control
The quality of mRNA is critical and should be strictly monitored during vaccine development. To accelerate the development of mRNA vaccines, we provide comprehensive, customer-oriented testing services for quality control of mRNA vaccines in accordance with requirements and guidelines for gene therapy products. Our services include a wide range of mRNA characterization, potency testing, safety, and toxicity testing.
If you are interested in learning more about our PC vaccine development services, would like to learn more about our services and opportunities to participate in market research, or are interested in a potential partnership or collaboration, please feel free to contact us. We look forward to working with you!
- Dai, Hong, et al. "Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy." Frontiers in Cell and Developmental Biology 10 (2022).
- Miao, Lei, Yu Zhang, and Leaf Huang. "mRNA vaccine for cancer immunotherapy." Molecular Cancer 20.1 (2021): 1-23.
- Huang, Xing, et al. "Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development." Molecular Cancer 20.1 (2021): 1-18.